Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011

Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference


//health-fitness.news-articles.net/content/2011/ .. annual-piper-jaffray-health-care-conference.html
Published in Health and Fitness on Tuesday, November 22nd 2011 at 13:11 GMT by Market Wire   Print publication without navigation


Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference -- SEATTLE, Nov. 22, 2011 /PRNewswire/ --

Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference

[ ]

SEATTLE, Nov. 22, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference taking place in New York City next week.  The presentation is scheduled for Wednesday, November 30, 2011 at 2:00 p.m. Eastern Time.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

SOURCE Omeros Corporation

[ Back to top ]

RELATED LINKS
[ http://www.omeros.com ]


Publication Contributing Sources